Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Bangkok Genomics Innovation PCL EV-to-EBITDA?
Bangkok Genomics Innovation PCLBKK:BKGI 46 EV-to-EBITDA is 9.43 as of Sep. 15, 2026, which is 22% below its 10-year median of 12.03. GuruFocus rates BKK:BKGI with a GF Score™ of 46/100. The stock has 11 warning signs investors should review. Among 124 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 70.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bangkok Genomics Innovation PCL's enterprise value is ฿1,217.8 Mil.
Bangkok Genomics Innovation PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ฿129.2 Mil. Therefore, Bangkok Genomics Innovation PCL's EV-to-EBITDA for today is 9.43.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's EV-to-EBITDA or its related term are showing as below:
BKK:BKGI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.76 Med: 12.03 Max: 63.13
Current: 9.43
During the past 7 years, the highest EV-to-EBITDA of Bangkok Genomics Innovation PCL was 63.13. The lowest was 4.76. And the median was 12.03.
BKK:BKGI's EV-to-EBITDA is ranked better than 70.16% of 124
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.195
vs BKK:BKGI: 9.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bangkok Genomics Innovation PCL's PE Ratio (TTM) for today is calculated as:
Bangkok Genomics Innovation PCL's share price for today is ฿2.38.
Bangkok Genomics Innovation PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.159.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's EV-to-EBITDA falls into.
Bangkok Genomics Innovation PCL's current Enterprise Value is ฿1,217.8 Mil.
Bangkok Genomics Innovation PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿129.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a EV-to-EBITDA of 9.43 as of Sep. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bangkok Genomics Innovation PCL. This is 22% below median its historical median of 12.03. Over the past decade, Bangkok Genomics Innovation PCL's EV-to-EBITDA has ranged from 4.76 to 63.13. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #37 out of 124 companies in the Medical Diagnostics & Research industry, placing it in the top 29.8%.
Is Bangkok Genomics Innovation PCL's EV-to-EBITDA too high?
Bangkok Genomics Innovation PCL's current EV-to-EBITDA of 9.43 is 22% below median its 10-year median of 12.03. Over the past 10 years, this metric has ranged from a low of 4.76 to a high of 63.13. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.20. Bangkok Genomics Innovation PCL's value of 9.43 is 41.8% below this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #37 out of 124 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #37 out of 124 companies for EV-to-EBITDA. This puts Bangkok Genomics Innovation PCL in the upper half of its industry. The industry median EV-to-EBITDA is 16.20. Bangkok Genomics Innovation PCL's value of 9.43 is 41.8% below this benchmark. Historically, Bangkok Genomics Innovation PCL's own EV-to-EBITDA has ranged from 4.76 to 63.13 over the past decade. While the company's 10-year median is 12.03 vs. the industry median of 16.20, Bangkok Genomics Innovation PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.20, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current EV-to-EBITDA of 9.43 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bangkok Genomics Innovation PCL. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current EV-to-EBITDA is 9.43, which is 22% below median its own 10-year median of 12.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current EV-to-EBITDA of 9.43. The current EV-to-EBITDA is 9.43, which is 22% below median its 10-year median of 12.03 and 41.8% below the Medical Diagnostics & Research industry median of 16.20. Bangkok Genomics Innovation PCL's overall GF Score™ is 46/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current EV-to-EBITDA is 9.43 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
46GF Score
Get the complete analysis for BKK:BKGI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
